Pfizer Buys Metsera for $5 Billion
Reading
Pfizer wants to buy Metsera for about $5 billion. Pfizer stopped making its own obesity medicine some time ago. Now, Pfizer wants to join the growing obesity treatment market.
Pfizer will pay $47.50 for each Metsera share. This is more than the share price from last Friday. Pfizer might pay an extra $22.50 per share if Metsera does well.
Metsera does not sell any products yet. But they are testing five new medicines. Pfizer thinks Metsera has good knowledge and new treatment ideas.
The demand for obesity treatments is very high. People want to use medicines like Wegovy and Zepbound. These medicines can be costly, so more options could lower prices.
Both Pfizer and Metsera agree to the deal. Metsera's shareholders must also agree. The deal should be done by the end of this year, if regulators allow it.
Questions
How much does Pfizer want to pay for Metsera?
$5 billion.
What will Pfizer pay for each Metsera share?
$47.50.
Does Metsera sell any products yet?
No, Metsera does not sell any products yet.
Describe the article image
Look at the article image and describe what you see on it. You may either speak or write your answer there.
Discussion
Discuss this article with your AI tutor to practice. Your tutor will help you with vocabulary and grammar.
Read a new article every day anddiscuss it with AI at lingolette.com